Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China.
Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China.
Clin Chim Acta. 2015 May 20;445:85-90. doi: 10.1016/j.cca.2015.03.017. Epub 2015 Mar 20.
Human liver-type fatty acid-binding protein (hL-FABP), which is found in both the normal and the diseased human kidney, has been observed to bind free fatty acids. Recently, the predictive and prognostic value of L-FABP in kidney diseases has attracted considerable attention. Numerous studies have demonstrated that L-FABP is a promising biomarker of several kidney diseases, and it has also been shown to attenuate renal injury. We performed a literature review regarding the ability of L-FABP to identify patients at risk of developing kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD) and to protect the kidneys in the course of kidney disease.
人肝型脂肪酸结合蛋白（hL-FABP）在正常和患病的人类肾脏中均有发现，可结合游离脂肪酸。最近，L-FABP 在肾脏疾病中的预测和预后价值引起了相当大的关注。大量研究表明，L-FABP 是几种肾脏疾病的有前途的生物标志物，它还可以减轻肾脏损伤。我们对 L-FABP 识别发生肾脏疾病（包括急性肾损伤（AKI）和慢性肾脏病（CKD））风险的患者的能力以及在肾脏疾病过程中保护肾脏的能力进行了文献综述。
